Eli Lilly just raised its full-year revenue guidance by billions thanks to surging demand for Zepbound and Mounjaro, proving the weight-loss drug market is still underserved. Novo Nordisk's CEO separately confirmed that Wegovy profitability will keep impr

Verdict: wait for a working signal before riding GLP-1 momentum

The GLP-1 investment thesis is genuinely compelling: Eli Lilly's 44.7% revenue growth and near-doubling of EPS validate that weight-loss demand remains underserved, per the CNBC and MarketWatch reports. But the trade mechanism designed to capture this thesis is broken — the entry rules require price to be simultaneously at or below $2.00 and above $2.00, a contradiction that produced zero triggers across 1,236 bars over 60 months, and no robust parameter setup was established before publication. Even setting aside the signal failure, Novo Nordisk's deteriorating fundamentals (revenue growth collapsing to 6.4%, operating margin compressing from 44.2% to 41.3%, and a negative 51.0% annualized return with a Sharpe of -1.02) undercut the idea's claim that the entire category is expanding margins together. The strongest single name, Lilly, trades just 1.6% below its $1,200 resistance but shows an ADX of only 7.8 — far below the 25 trend-strength threshold the thesis requires. **Conviction breakdown:** Thesis support is moderate (65) because Lilly's fundamentals are exceptional but the basket-level argument is fractured by Novo's decline. Trade readiness is very low (15) given the contradictory entry conditions and absence of any validated setup. Risk quality is weak (35) with NVO's 74.6% drawdown dragging portfolio Sharpe to -0.33. Trigger proximity is near zero (5) because the price gate is unsatisfiable. Fundamentals trend is split (55) — Lilly's momentum is offset by NVO's margin compression and ITGR's 14.0% EPS decline.

Trade now

This is a watch-list setup, not an active signal. The strategy's entry conditions were evaluated across 1,236 daily bars over 60 months for LLY and did not open a single trade. The rules require the closing price to be both at or below $2.00 and above $2.00 simultaneously — a contradiction that can never be satisfied — alongside an ADX (14) above 25 and a low touching the 38.2% Fibonacci retracement. The research author flagged these price gates as compilation errors and has requested a bounded optimization to relax them while preserving the core ADX trend filter. No robust setup was established before publication, so there is no live entry zone, distance-to-trigger, or reward-to-risk figure to act on today. The thesis itself is straightforward: wait for a pullback toward the 50-day moving average on LLY, then enter long on bullish confirmation while trend strength remains elevated. The trend filter is already active for ITGR (ADX at 92.2, well above the 25 threshold) and NVO (ADX at 29.0), but LLY shows an ADX of just 7.8 — far below the entry requirement. The idea argues that surging Zepbound and Mounjaro demand validates the entire GLP-1 category, with KKR's $4.3 billion buyout of Integer Holdings providing a floor for related medical device suppliers. "Wait" means concretely that the entry rules need to be corrected and re-evaluated before any position can be considered. The nearest support for LLY sits near $1,111 and nearest resistance at $1,200, but without a functional entry trigger those levels are reference points, not actionable zones. Once the contradictory price gates are resolved, the stop loss is defined at the 61.8% Fibonacci retracement or a fixed 2.4% unrealized loss, with take-profit targets at the nearest resistance level or a 4.8% gain.

Why the GLP-1 demand story still has fuel

The bull case centers on Eli Lilly's undeniable fundamental momentum. Per the CNBC and MarketWatch reports, the company raised its full-year guidance on the back of surging Zepbound and Mounjaro demand. The fundamentals confirm the narrative: Lilly posted 44.7% year-over-year revenue growth, reaching $65.2B in revenue, with a peer-percentile ranking in the 59th percentile for growth. Its gross margin sits at an exceptional 83.0% (79th percentile among health care peers), and diluted EPS nearly doubled, growing 96.0% year-over-year to $22.95. Return on equity of 77.8% places it in the 90th percentile — this is a company converting massive top-line demand into shareholder returns. The thesis that the weight-loss market is still underserved is difficult to argue against when the category leader is putting up numbers like these. Novo Nordisk's inclusion makes the category-wide argument rather than a single-stock bet. The idea's thesis cites the Bloomberg report confirming that Wegovy profitability will keep improving as the drug launches in new countries. The numbers show a company still generating enormous cash: $58.96B in free cash flow…

Scores

• Conviction score breakdown: 35
• Thesis support: 65
• Trade readiness: 15
• Risk quality: 35
• Trigger proximity: 5
• Fundamentals trend: 55

Watch items

• LLY — ADX (14)
• LLY — RSI (14)
• ITGR — RSI (14)
• NVO — ADX (14)
• LLY — Price vs. $1,200 resistance
• ITGR — Price
• ITGR — Price above 2
• ITGR — ADX (14) above 25